Project Grant R44AI192180
Award Date
6/9/25
Completion Date
5/31/26
Dollars Obligated
$295K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Hawaii (UH) to study the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The key objectives are to determine the baseline dengue virus serostatus of Dengvaxia recipients, assess the long-term safety and effectiveness of the vaccine, and characterize the antibody and...
This $1,211,704 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a comprehensive study to elucidate the pathogenesis of severe dengue disease during primary infections. The research aims to determine differences in innate immune responses, antibody functions, and T-cell responses between severe primary and secondary dengue infections. The study will leverage...
This $781,718 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel T cell-based vaccine to prevent Dengue virus (DENV) and Zika virus (ZIKV) infection. The award aims to design a vaccine that expresses ubiquitinated and rearranged ZIKV/DENV1-4 non-structural protein 3 (NS3) to induce cytotoxic T lymphocyte (CTL) responses without causing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,969 Project Grant to L2 Diagnostics LLC under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to evaluate a mosquito salivary protein, AGBR1, as a potential vaccine candidate against Chikungunya virus, an arboviral disease transmitted by infected mosquitoes. The project aims to conduct comparative assessments of different AGBR1 vaccine formulations, including...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $142,908 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the San Diego Biomedical Research Institute. The grant, awarded on November 11, 2024, supports research to define the role of antibody glycosylation in regulating natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) during HIV infection. The project aims to determine how specific antibody...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $738,445 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University to develop an mRNA-based multivalent malaria vaccine. The project aims to optimize mRNA vaccine-induced antibody-mediated and cell-mediated immune responses targeting pre-erythrocytic and blood-stage malaria parasites. Specifically, the grant will support the design, production, and evaluation of mRNA vaccine candidates...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $561,538 to Abwiz Bio Inc. to develop neutralizing antibodies against Machupo virus, a New World arenavirus. The project aims to utilize an innovative, stabilized-trimer immunogen to discover and characterize antibodies targeting critical sites on the virus surface glycoprotein, in addition to the receptor-binding...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $626,423 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB). The funding will support research to explore the dependence of arenaviruses on the metabolism of the monosaccharides D-glucose and D-mannose, with the goal of developing carbohydrate antimetabolite compounds as potential pan-arenavirus therapeutics. Specifically,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
This $699,339 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research on dengue and Zika virus transmission dynamics in northwestern coastal Ecuador. The primary awardee, the Regents of the University of Michigan, will lead a multi-institutional effort to characterize how environmental, social, and biological factors drive arbovirus transmission across diverse landscapes and...